Long-term acid suppression causes hip fractures and pneumonia.

Original statement

حمض المعدة ليس عدوّاً يجب قمعه، بل أداة أساسية للهضم وقتل الميكروبات وامتصاص الحديد وفيتامين ب12 والكالسيوم والمغنيزيوم. تثبيطه لفترات طويلة بـ PPIs (أوميبرازول، نكسيم، كونترلوك) أو مثبطات H2 ينقلب على الجسم: مرض كلوي مزمن، فرط نمو بكتيري، عدوى مطثية عسيرة، التهاب رئوي، نقص B12 والمغنيزيوم، كسور ورك، تغيّر الميكروبيوم، وزيادة الوفيات. والأخطر أنّ الجسم يدمن الدواء عبر فرط الإفراز الارتدادي بعد الإيقاف، فيتحوّل الاستخدام القصير إلى اعتماد مزمن.

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

Long-term acid suppression causes hip fractures and pneumonia.

Origin

Source status

Archive editors

Attribution

Archive editors (eltayebat.com); not verified as Elawady's own words

Origin

https://eltayebat.com/rule/acid-blockers/

Attribution uncertainty

Written by the archive operators; study selection is the archive's, not necessarily Elawady's.

Claimed mechanism

Reduced calcium absorption (bone); loss of acid barrier (pneumonia).

Claimed health effect

Hip fracture; community- and hospital-acquired pneumonia.

Population concerned

Long-term PPI users, older adults.

Geographic restriction by Elawady

none found

Scientific assessment

Unclear / insufficient evidence – The data do not allow an assessment either way.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

PPIs cause hip fractures and pneumonia.

2. What is demonstrably correct?

Associations exist: GPRD nested case-control AOR 1.44 (1.30–1.59) for >1 year of PPI, AOR 2.65 for long-term high dose; meta-analysis of observational studies OR 1.27 (1.11–1.46) for pneumonia.

3. What is wrong or exaggerated?

The archive presents these as proven effects ('raised hip fracture risk 44%'). Case-control and cohort designs cannot exclude confounding (frailty, comorbidity). The pneumonia estimate is very heterogeneous.

4. What remains unclear?

Whether long exposure (>3 years) has a small causal effect on fracture is not settled.

5. Which studies support it?

A-PPI-07, A-PPI-08.

6. Which studies contradict it?

COMPASS (I-PPI-01): no statistically significant difference in fractures or pneumonia with pantoprazole vs placebo.

7. What applies to Germany and Europe?

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

8. What is known about Egypt?

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

9. What practical conclusion is appropriate?

Use the lowest effective dose for an indicated duration; fracture and pneumonia risk alone are not, per AGA guidance, reasons to stop an indicated PPI.

Assessment details

Rationale for certainty of evidence

Observational associations with dose-duration gradients (hip fracture OR 1.44 after >1 year; pneumonia OR 1.27 with high heterogeneity, I² 90.5%); the COMPASS RCT found no significant difference in fractures or pneumonia over 3 years.

Source quality

Correctly cited observational studies; causal language overstated.

Regional transferability

Moderate–high.

Individual exceptions

Older people with other fracture risks may be more affected if an effect exists.

Regional scope of the claim

general (biological/medical)

Last reviewed

25 October 2026 provisional

In plain language

Several studies saw more hip fractures and pneumonias among people taking acid blockers for a long time. A large randomised trial did not confirm this over three years. A small effect is possible but not proven.

Studies on this claim

Regional context

Germany / EU

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

Egypt

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

What applies in my country?

General scientific assessment

Unclear / insufficient evidence Unclear: observational studies link long-term PPI use with hip fracture and pneumonia, but the largest randomised trial did not confirm these risks.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

1. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis.. Eom CS et al.. CMAJ 2011 · PMID 21173070 · DOI 10.1503/cmaj.092129
2. Long-term proton pump inhibitor therapy and risk of hip fracture.. Yang YX et al.. JAMA 2006 · PMID 17190895 · DOI 10.1001/jama.296.24.2947
3. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.. Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056
4. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.. Freedberg DE et al.. Gastroenterology 2017 · PMID 28257716 · DOI 10.1053/j.gastro.2017.01.031